Strategic Timing of Antiretroviral Treatment

Objective: To find out if the chance of developing a serious illness or of getting AIDS is less if patients start taking HIV medicines at a time when their CD4-positive cell count is still fairly high. To learn more about how a strategy of starting HIV medicines early might affect other aspects of care, such as the chances of developing other illnesses or resistance to HIV medicines, the frequency of doctor visits, the cost of medical care, and general health and satisfaction.

Sponsor: University of Minnesota (in collaboration with NIH and VA)

Contact: James D Neaton, PhD University of Minnesota - Clinical and Translational Science Institute

Study ID: NCT00867048

Status: Currently recruiting

Two-Stage Tuberculin (PPD) Skin Testing in Individuals With HIV Infection

Objective: To quantitate the percentage of patients in an HIV-infected population who demonstrate the “booster” phenomenon (attainment of a positive response to a second tuberculin purified protein derivative skin test when the first skin test was negative); to determine the relationship between the booster phenomenon and CD4-positive lymphocyte cell counts; to detect any relationship between the booster phenomenon and HIV exposure category.

Sponsor: NIAID

Contact: Rona Siskind, Division of Acquired Immunodeficiency Syndrome, NIAID

Study ID: NCT00000955

Status: Ongoing

Acute Respiratory Infection Consortium

Objective: A proposed observational, longitudinal study of influenza-like illness (ILI) among active duty military members, healthy retirees, and their dependents recruited from both inpatient and outpatient settings of military treatment facilities in the continental US to be followed for a total of four visits over a 28-day period. Investigators also propose to conduct a household-based study of influenza in which individuals who have a laboratory-confirmed influenza illness will be recruited and enrolled along with their family members for the purpose of studying transmission of influenza within households. Taken together, these studies will establish a longitudinal cohort of ILI among active duty members and their families, as well as a repository of biological specimens relevant to the epidemiology and immunology of infection.

Sponsor: NIAID

Contact: Martin Ottolini, MD, 301-295-1546, mottolini@usuhs.mil

Study ID: NCT01021098

Status: Currently recruiting

Identification and Analysis of Immunomodulatory Molecules in Patients with Hematologic Disorders and Healthy Volunteers

Objective: To analyze the plasma and the cells in the immune system to learn how they work. These may influence why one person will develop an infection and another will not, or why one person develops severe symptoms of a disease while others remain without symptoms.

Sponsor: VA

Contact: Juan J Toro, MD 210-617-5300 ext 16777, juantoro2@va.gov

Study ID: NCT00223483

Status: Currently recruiting

Stem Cell Transplant, Busulfan, Melphalan, and Alemtuzumab in Treating Patients with Hematologic Cancer (Phase II)

Objective: This phase II trial is studying the side effects of giving a stem cell transplant together with busulfan, melphalan, and alemtuzumab to see how well it works in treating patients with hematologic cancer.

Sponsor: NCI

Contact: Andrew M Yeager, MD, University of Arizona

Study ID: NCT00840424

Status: Ongoing

back to February articles